Results 101 to 110 of about 218,086 (209)

Creating Markets for New Vaccines Part I: Rationale [PDF]

Malaria, tuberculosis, and the strains of HIV common in Africa kill approximately 5 million people each year. Yet research on vaccines for these diseases remains minimal largely because potential vaccine developers fear that they would not be able to ...
Michael Kremer
core  

Creating Markets for New Vaccines Part II: Design Issues [PDF]

Several programs have been proposed to improve incentives for research on vaccines for malaria, tuberculosis, and HIV, and to help increase accessibility of vaccines once they are developed.
Michael Kremer
core  

Stopping poliovirus vaccination after eradication: issues and challenges

Bulletin of the World Health Organization
Since 1988 reported polio cases worldwide have declined by about 85% and the number of known or suspected polioendemic countries has decreased from over 120 to less than 50. With eradication of poliomyelitis approaching, issues potentially affecting when
D.J. Wood, R.W. Sutter, W.R. Dowdle
doaj   +1 more source

Acknowledgement to Reviewers of Vaccines in 2015

, 2016
The editors of Vaccines would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2015.
Vaccines Editorial Office
core   +1 more source

Vaccines against cholera, typhoid fever and shigellosis for developing countries.

, 2004
Enteric diseases, such as cholera, typhoid fever and shigellosis, still produce a significant burden, especially among the poor in countries where these illnesses are endemic.
Ochiai, RL, Deen, JL, Lee, HJ, Acosta, CJ, von Seidlein, L, Galindo, CM, Carbis, R, Clemens, JD   +7 more
core   +1 more source

A novel approach to poliovirus vaccine neurovirulence testing: development of an enhanced 4-level scoring system

Immunobiology
The ongoing promotion and administration of vaccines play a critical role in the global effort to eradicate poliovirus. The Monkey Neurovirulence Test (MNVT) is an essential method for evaluating the neurovirulence of viruses in both the Oral Attenuated ...
Xi Wang, Yunguang Hu, Anguo Yin, Changxu Chen, Hong Xiang, Li Wang, Bochuan Liu, Yuan Tian, Yu Gao, Mingrun Zhang, Yan Li, Yina Cun, Jian Zhou   +12 more
doaj   +1 more source

Acknowledgement to Reviewers of Vaccines in 2016

, 2017
The editors of Vaccines would like to express their sincere gratitude to the following reviewers for assessing manuscripts in 2016.[...
Vaccines Editorial Office
core   +1 more source

Recombinant expression systems for production of stabilised virus-like particles as next-generation polio vaccines

Nature Communications
Polioviruses have caused crippling disease in humans for centuries, prior to the successful development of vaccines in the mid-1900’s, which dramatically reduced disease prevalence.
Lee Sherry, Mohammad W. Bahar, Claudine Porta, Helen Fox, Keith Grehan, Veronica Nasta, Helen M. E. Duyvesteyn, Luigi De Colibus, Johanna Marsian, Inga Murdoch, Daniel Ponndorf, Seong-Ryong Kim, Sachin Shah, Sarah Carlyle, Jessica J. Swanson, Sue Matthews, Clare Nicol, George P. Lomonossoff, Andrew J. Macadam, Elizabeth E. Fry, David I. Stuart, Nicola J. Stonehouse, David J. Rowlands   +22 more
doaj   +1 more source

The Immunogenicity of Monovalent Oral Poliovirus Vaccine Type 1 (mOPV1) and Inactivated Poliovirus Vaccine (IPV) in the EPI Schedule of India

Vaccines
Background: In 2016, the Global Polio Eradication Initiative (GPEI) recommended the cessation of using type 2 oral poliovirus vaccine (OPV) and OPV, with countries having to switch from the trivalent to bivalent OPV (bOPV) with the addition of ...
Lalitendu Mohanty, T. Jacob John, Shailesh D. Pawar, Padmasani Venkat Ramanan, Sharad Agarkhedkar, Pradeep Haldar   +5 more
doaj   +1 more source

Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials.

Lancet Microbe, 2022
Wahid R, Mercer LD, De Leon T, DeAntonio R, Sáez-Llorens X, Macadam A, Chumakov K, Strating J, Koel B, Konopka-Anstadt JL, Oberste MS, Burns CC, Andino R, Tritama E, Bandyopadhyay AS, Aguirre G, Rüttimann R, Gast C, Konz JO.   +18 more
europepmc   +1 more source